Life Science Startups Rising

Join Our Mailing List

Life Science Startups Rising in the UK

Stephen Chambers spent 22 years in some of the most innovative companies in life science as the director of gene expression and then as a co-founder of his own company.

Here’s his story

Today he runs SynbiCITE, the UK’s synthetic biology consortium of 56 industrial partners and 19 Academic institutions located at Imperial College in London.

Stephen and SynbiCITE, just launched the world’s first Lean LaunchPad for Synthetic Biology program.


steve blank

By Steve Blank


Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact:


Product DetailsProduct Details

3 Responses

  1. “A digital disruption is playing out in healthcare, as witnessed by the emergence of new business models and technology that will change the nature of patient interactions, alter consumer expectations and ultimately improve health outcomes.”

    Rick Ratliff
    [Managing Director Of Digital Health Solutions]


  2. Start-Ups Rising

    I do believe that start-up plans can succeed in the current market environment. Having said this, failures have been common. My favorite model for successful startups are new health plans serving Medicare Advantage members that are linked to health systems.

    To be successful any health plan has to offer lower costs, higher perceived value and overcome distribution barriers. MA plans linked to health systems offer the possibility of lower costs through integrated care, a “halo of quality” from the associated health system and, since the MA product is sold to the individual market, is intrinsically beyond the confines of the employer-based market.

    Realizing success depends on excellence in execution. Effective execution requires either the rethinking of the health system’s business model, or at least a commitment that the health plan should maintain operating its integrity. That there have been many failures among health system sponsored plans indicates that this is easier said than done.

    Douglas Sherlock CFA
    [Senior Health Care Analyst]
    Sherlock Company


  3. Questionable “Young Blood” Transfusions Offered in U.S. as Anti-Aging Remedy

    A startup called Ambrosia will fill your veins with the blood of young people and empty your pockets of $8,000.

    Ann Miller RN MHA


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: